Spark Therapeutics Company Profile (NASDAQ:ONCE)

About Spark Therapeutics

Spark Therapeutics logoSpark Therapeutics, Inc. (Spark) is engaged in developing products in the field of gene therapy. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its SPK-RPE65 (voretigene neparvovec) targets genetic blinding conditions known as inherited retinal dystrophies (IRDs). Its product candidates include SPK-CHM and SPK-FIX. Its product development portfolio includes product candidates targeting expression of genes in the liver, with an initial focus on hematologic disorders. It is engaged in the development and commercialization of SPK-FIX product candidates for the treatment of hemophilia B. The Company is developing a lead product candidate for the treatment of a form of Batten disease in SPK-TPP1 program. The Company is also conducting preclinical studies on a product candidate for the treatment of Huntington's disease, a hereditary genetic disorder.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ONCE
  • CUSIP:
Key Metrics:
  • Previous Close: $62.21
  • 50 Day Moving Average: $59.16
  • 200 Day Moving Average: $47.73
  • 52-Week Range: $21.20 - $66.00
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -15.36
  • P/E Growth: 0.00
  • Market Cap: $1.84B
  • Outstanding Shares: 30,621,000
  • Beta: 3.31
Profitability:
  • Net Margins: -366.76%
  • Return on Equity: -26.96%
  • Return on Assets: -23.90%
Debt:
  • Current Ratio: 18.02%
  • Quick Ratio: 18.03%
Additional Links:
Companies Related to Spark Therapeutics:

Analyst Ratings

Consensus Ratings for Spark Therapeutics (NASDAQ:ONCE) (?)
Ratings Breakdown: 1 Sell Rating, 4 Hold Ratings, 8 Buy Ratings
Consensus Rating:Buy (Score: 2.54)
Consensus Price Target: $61.90 (2.79% upside)
Analysts' Ratings History for Spark Therapeutics (NASDAQ:ONCE)
Show:
DateFirmActionRatingPrice TargetDetails
9/2/2016Stifel NicolausInitiated CoverageBuy$73.00View Rating Details
8/11/2016Cantor FitzgeraldReiterated RatingBuy$94.00View Rating Details
8/10/2016WedbushReiterated RatingUnderperform$28.00 -> $29.00View Rating Details
8/5/2016Jefferies GroupReiterated RatingHoldView Rating Details
7/21/2016Chardan CapitalSet Price TargetHold$35.00View Rating Details
7/12/2016Royal Bank Of CanadaInitiated CoverageOutperform$70.00View Rating Details
6/21/2016SunTrust Banks Inc.Boost Price TargetBuy$64.00 -> $72.00View Rating Details
5/19/2016Cowen and CompanyReiterated RatingBuy$75.00View Rating Details
4/12/2016Evercore ISIInitiated CoverageBuy$37.00View Rating Details
3/30/2016Goldman Sachs Group Inc.Initiated CoverageBuy -> Neutral$44.00View Rating Details
1/12/2016JPMorgan Chase & Co.Reiterated RatingOverweightView Rating Details
12/24/2015WunderlichDowngradeBuy -> HoldView Rating Details
10/11/2015Roth CapitalReiterated RatingBuyView Rating Details
5/6/2015Credit Suisse Group AGInitiated CoverageOutperform$76.00View Rating Details
2/25/2015Sanford C. BernsteinInitiated CoverageMarket PerformView Rating Details
2/22/2015Rodman & RenshawInitiated CoverageBuy$71.00View Rating Details
(Data available from 9/24/2014 forward)

Earnings

Earnings History for Spark Therapeutics (NASDAQ:ONCE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2016        
8/10/2016Q216($0.97)($1.04)$1.17 million$1.29 millionViewListenView Earnings Details
5/4/2016Q116($0.84)($0.95)$1.48 million$1.29 millionViewListenView Earnings Details
3/9/2016Q415($0.73)($0.24)ViewListenView Earnings Details
11/4/2015Q315($0.48)($0.70)$4.43 million$1.30 millionViewListenView Earnings Details
8/5/2015Q215($0.13)($0.60)$4.50 million$1.29 millionViewListenView Earnings Details
5/6/2015Q115($0.61)($0.58)$1.20 million$1.30 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Spark Therapeutics (NASDAQ:ONCE)
Current Year EPS Consensus Estimate: $-4.03 EPS
Next Year EPS Consensus Estimate: $-3.92 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($1.04)($0.80)($0.88)
Q2 20164($0.97)($0.83)($0.88)
Q3 20164($1.01)($0.95)($0.97)
Q4 20164($1.06)($0.99)($1.02)
Q1 20171($1.03)($1.03)($1.03)
Q2 20171($1.07)($1.07)($1.07)
Q3 20171($1.09)($1.09)($1.09)
Q4 20171($1.11)($1.11)($1.11)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Spark Therapeutics (NASDAQ:ONCE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Spark Therapeutics (NASDAQ:ONCE)
Insider Ownership Percentage: 9.60%
Institutional Ownership Percentage: 78.79%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/16/2016Jeffrey D MarrazzoCEOSell10,000$62.68$626,800.00View SEC Filing  
9/15/2016Katherine A HighInsiderSell10,000$60.37$603,700.00View SEC Filing  
8/16/2016Hospital Of Philade Children'sDirectorSell1,000,000$60.90$60,900,000.00View SEC Filing  
8/11/2016Anand MehraDirectorSell29,963$60.13$1,801,675.19View SEC Filing  
8/11/2016Jeffrey D MarrazzoCEOSell16,970$60.04$1,018,878.80View SEC Filing  
8/10/2016Katherine A HighInsiderSell1,890$60.00$113,400.00View SEC Filing  
8/8/2016Anand MehraDirectorSell100$60.47$6,047.00View SEC Filing  
8/8/2016Jeffrey D MarrazzoCEOSell900$60.24$54,216.00View SEC Filing  
8/8/2016Katherine A HighInsiderSell500$60.24$30,120.00View SEC Filing  
8/4/2016Anand MehraDirectorSell5,064$60.00$303,840.00View SEC Filing  
8/3/2016Jeffrey D MarrazzoCEOSell16,530$60.02$992,130.60View SEC Filing  
8/3/2016Katherine A HighInsiderSell17,610$60.02$1,056,952.20View SEC Filing  
8/1/2016Anand MehraDirectorSell22,665$60.03$1,360,579.95View SEC Filing  
8/1/2016Jeffrey D MarrazzoCEOSell12,348$60.03$741,250.44View SEC Filing  
8/1/2016Katherine A HighInsiderSell13,983$60.02$839,259.66View SEC Filing  
7/18/2016Jeffrey D MarrazzoCEOSell5,000$52.53$262,650.00View SEC Filing  
7/15/2016Coelho Rogerio VivaldiInsiderSell7,000$53.03$371,210.00View SEC Filing  
7/5/2016Barge Joseph LaInsiderSell3,000$52.24$156,720.00View SEC Filing  
6/20/2016Hospital Of Philade Children'sMajor ShareholderSell1,000,000$42.30$42,300,000.00View SEC Filing  
6/15/2016Jeffrey D MarrazzoCEOSell5,000$46.49$232,450.00View SEC Filing  
5/31/2016Anand MehraDirectorSell500$60.00$30,000.00View SEC Filing  
5/23/2016Katherine A HighInsiderSell10,000$54.42$544,200.00View SEC Filing  
5/20/2016Barge Joseph LaInsiderSell10,000$47.65$476,500.00View SEC Filing  
5/20/2016Stephen W WebsterCFOSell20,000$50.39$1,007,800.00View SEC Filing  
5/19/2016Jeffrey D MarrazzoCEOSell25,000$46.01$1,150,250.00View SEC Filing  
4/21/2016Coelho Rogerio VivaldiInsiderSell7,000$40.02$280,140.00View SEC Filing  
12/28/2015Hospital Of Philade Children'sMajor ShareholderSell131,505$44.18$5,809,890.90View SEC Filing  
12/21/2015Hospital Of Philade Children'sMajor ShareholderSell1,000,000$44.18$44,180,000.00View SEC Filing  
12/1/2015Katherine A HighInsiderSell10,000$55.31$553,100.00View SEC Filing  
11/27/2015Anand MehraDirectorSell22,961$60.01$1,377,889.61View SEC Filing  
11/16/2015Katherine A HighInsiderSell10,000$53.77$537,700.00View SEC Filing  
11/12/2015Anand MehraDirectorSell130,605$60.11$7,850,666.55View SEC Filing  
10/14/2015Katherine A. HighinsiderSell30,000$49.34$1,480,200.00View SEC Filing  
10/13/2015Katherine A. HighinsiderSell10,000$48.00$480,000.00View SEC Filing  
10/12/2015Jeffrey D. MarrazzoCEOSell75,000$48.35$3,626,250.00View SEC Filing  
10/9/2015Jeffrey D. MarrazzoCEOSell75,000$47.82$3,586,500.00View SEC Filing  
10/8/2015Anand MehraDirectorSell529,544$45.46$24,073,070.24View SEC Filing  
10/7/2015Coelho Rogerio VivaldiinsiderSell41,000$48.85$2,002,850.00View SEC Filing  
10/7/2015Stephen W. WebsterCFOSell20,000$48.86$977,200.00View SEC Filing  
10/7/2015Steven AltschulerDirectorBuy5,000$49.11$245,550.00View SEC Filing  
2/4/2015Anand MehraDirectorBuy225,000$23.00$5,175,000.00View SEC Filing  
2/4/2015Hospital Of Philade Children'sMajor ShareholderBuy100,000$23.00$2,300,000.00View SEC Filing  
2/4/2015Stephen W WebsterCFOBuy2,500$23.00$57,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Spark Therapeutics (NASDAQ:ONCE)
DateHeadline
News IconStock Perspective: Spark Therapeutics, Inc. (NASDAQ:ONCE) Earnings in View - Frisco Fastball (NASDAQ:ONCE)
friscofastball.com - September 22 at 11:25 AM
finance.yahoo.com logoSpark Therapeutics to Participate in Multiple Upcoming Conferences (NASDAQ:ONCE)
finance.yahoo.com - September 21 at 10:41 AM
News IconAn intrinsic value calculation for Spark Therapeutics Inc (ONCE) shows investors are overpaying - Simply Wall St (NASDAQ:ONCE)
simplywall.st - September 20 at 11:52 AM
nasdaq.com logoSpark Therapeutics Reaches Analyst Target Price (NASDAQ:ONCE)
www.nasdaq.com - September 17 at 11:02 AM
nasdaq.com logoSpark Therapeutics Reaches Analyst Target Price - Nasdaq (NASDAQ:ONCE)
www.nasdaq.com - September 16 at 6:24 PM
News IconShares Holding Above Moving Averages: Spark Therapeutics, Inc. (NASDAQ:ONCE) - Post News (NASDAQ:ONCE)
www.kentuckypostnews.com - September 15 at 10:03 AM
News IconDoes Spark Therapeutics Inc Have Any Gas After Today's Huge Increase? - Chester News (NASDAQ:ONCE)
www.chesterindependent.com - September 15 at 10:03 AM
kcregister.com logoBig Movers: Spark Therapeutics, Inc. (NASDAQ:ONCE), Cherokee Inc. (NASDAQ:CHKE), New Jersey Resources Corp ... - KC Register (NASDAQ:ONCE)
www.kcregister.com - September 12 at 11:09 AM
News IconSell-side Consensus Sees Spark Therapeutics, Inc. (NASDAQ:ONCE) Going Where Near-Term? - Frisco Fastball (NASDAQ:ONCE)
friscofastball.com - September 9 at 6:13 PM
News IconStock Sliding Down Over the Last Month: Spark Therapeutics, Inc. (NASDAQ:ONCE) - Post News (NASDAQ:ONCE)
www.kentuckypostnews.com - September 8 at 10:25 AM
wsj.com logo[$$] Health-Care Returns Outpace Tech as Advances Reshape Industry (NASDAQ:ONCE)
www.wsj.com - September 6 at 11:22 AM
247wallst.com logoTop Analyst Upgrades and Downgrades: Carnival, Ciena, MercadoLibre, Spark Therapeutics, Smith & Wesson, Teva ... - 24/7 Wall St. (NASDAQ:ONCE)
247wallst.com - September 2 at 6:32 PM
finance.yahoo.com logoSpark Therapeutics to Participate in Multiple September Conferences (NASDAQ:ONCE)
finance.yahoo.com - August 31 at 11:38 AM
realistinvestor.com logoSpark Therapeutics, Inc. (NASDAQ:ONCE) Is Expected To Post EPS Of $-1.09 - RealistInvestor.com (NASDAQ:ONCE)
www.realistinvestor.com - August 30 at 6:35 PM
capitalcube.com logoETF’s with exposure to Spark Therapeutics, Inc. : August 30, 2016 (NASDAQ:ONCE)
www.capitalcube.com - August 30 at 6:35 PM
capitalcube.com logoSpark Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : ONCE-US : August 29, 2016 (NASDAQ:ONCE)
www.capitalcube.com - August 29 at 6:26 PM
247wallst.com logoLots of Insiders Are Selling Apple, Facebook, Activision Blizzard and More (NASDAQ:ONCE)
247wallst.com - August 21 at 10:42 AM
finance.yahoo.com logoSPARK THERAPEUTICS, INC. Financials (NASDAQ:ONCE)
finance.yahoo.com - August 20 at 6:18 PM
investornewswire.com logoWill Spark Therapeutics, Inc. (NASDAQ:ONCE) Hit $94 Price Target? - Investor Newswire (NASDAQ:ONCE)
www.investornewswire.com - August 15 at 6:58 PM
capitalcube.com logoETF’s with exposure to Spark Therapeutics, Inc. : August 15, 2016 (NASDAQ:ONCE)
www.capitalcube.com - August 15 at 6:58 PM
capitalcube.com logoSpark Therapeutics, Inc. :ONCE-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016 (NASDAQ:ONCE)
www.capitalcube.com - August 12 at 6:47 PM
News IconRecent Insider Trading : Spark Therapeutics Inc (NASDAQ:ONCE) - The Voice Registrar (NASDAQ:ONCE)
voiceregistrar.com - August 12 at 9:51 AM
finance.yahoo.com logoEdited Transcript of ONCE earnings conference call or presentation 10-Aug-16 12:30pm GMT (NASDAQ:ONCE)
finance.yahoo.com - August 11 at 9:53 AM
finance.yahoo.com logoSpark Therapeutics reports 2Q loss - Yahoo Finance (NASDAQ:ONCE)
finance.yahoo.com - August 10 at 7:06 PM
globenewswire.com logoSpark Therapeutics Announces New Positive Data from Continuation of Phase 3 Trial of Voretigene Neparvovec (NASDAQ:ONCE)
globenewswire.com - August 10 at 9:45 AM
sg.finance.yahoo.com logoSpark Therapeutics reports 2Q loss (NASDAQ:ONCE)
sg.finance.yahoo.com - August 10 at 9:45 AM
biz.yahoo.com logoSPARK THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, (NASDAQ:ONCE)
biz.yahoo.com - August 10 at 9:45 AM
zacks.com logoDrug Stock Earnings to Watch on Aug 10: ONCE, COLL & ARGS (NASDAQ:ONCE)
www.zacks.com - August 9 at 9:49 AM
twst.com logoSpark Therapeutics Inc.: Spark Therapeutics, Inc. to Host Conference Call on August 10th at 8:30a.m. to Discuss Second Quarter 2016 Results (NASDAQ:ONCE)
www.twst.com - August 2 at 11:33 AM
publicnow.com logoSpark Therapeutics, Inc. to Host Conference Call on August 10th at 8:30a.m. to Discuss Second Quarter 2016 Results (NASDAQ:ONCE)
www.publicnow.com - August 2 at 11:33 AM
News IconSpark Therapeutics, Inc. (NASDAQ:ONCE) Earnings Preview: Should Investors Be Nervous? - The Voice Registrar (NASDAQ:ONCE)
voiceregistrar.com - July 29 at 9:42 AM
ftsenews.co.uk logoSpark Therapeutics, Inc. (NASDAQ:ONCE) Updated Price Targets - FTSE News (NASDAQ:ONCE)
www.ftsenews.co.uk - July 27 at 9:41 AM
247wallst.com logoJPMorgan Bullish on Biotech: 3 Top Picks to Buy Now (NASDAQ:ONCE)
247wallst.com - July 27 at 8:20 AM
investornewswire.com logoCan Shares Of Spark Therapeutics, Inc. (NASDAQ:ONCE) Hit $94? - Investor Newswire (NASDAQ:ONCE)
www.investornewswire.com - July 26 at 9:52 AM
streetinsider.com logoSpark Therapeutics (ONCE), Pfizer (PFE) Offer Updated SPK-9001 Phase 1/2 Data in Hemophilia B - StreetInsider.com (NASDAQ:ONCE)
www.streetinsider.com - July 26 at 9:52 AM
streetinsider.com logoSpark Therapeutics (ONCE), Pfizer (PFE) Offer Updated SPK-9001 Phase 1/2 Data in Hemophilia B (NASDAQ:ONCE)
www.streetinsider.com - July 25 at 6:46 PM
globenewswire.com logoFirst four subjects all with follow up beyond 12 weeks without any need for immunosuppression (NASDAQ:ONCE)
globenewswire.com - July 25 at 11:04 AM
finance.yahoo.com logoSpark Therapeutics and Pfizer Announce Updated Data from First Cohort in Hemophilia B Phase 1/2 Trial … (NASDAQ:ONCE)
finance.yahoo.com - July 25 at 11:04 AM
nasdaq.com logoSpark Therapeutics, Pfizer Present Updated Data From Ongoing SPK-9001 Trial (NASDAQ:ONCE)
www.nasdaq.com - July 25 at 11:04 AM
publicnow.com logoSpark Therapeutics and Pfizer Announce Updated Data from First Cohort in Hemophilia B Phase 1/2 Trial Demonstrating Consistent, Sustained Therapeutic Levels of Factor IX Activity (NASDAQ:ONCE)
www.publicnow.com - July 25 at 8:48 AM
4-traders.com logoSpark Therapeutics : and Pfizer Announce Receipt of FDA Breakthrough Therapy Designation for SPK-9001 for the Treatment of Hemophilia B (NASDAQ:ONCE)
www.4-traders.com - July 23 at 6:10 PM
4-traders.com logoSpark Therapeutics : and Pfizer Announce Receipt of FDA Breakthrough Therapy Designation for SPK-9001 for the Treatment of Hemophilia B. (NASDAQ:ONCE)
www.4-traders.com - July 23 at 10:35 AM
News IconInstitutional Investors Are Buying Islet Sciences Inc (NASDAQ:ONCE) - Consumer Eagle (NASDAQ:ONCE)
www.consumereagle.com - July 22 at 6:31 PM
News IconEquity Roundup: Stock Performance Focus on Spark Therapeutics, Inc. (NASDAQ:ONCE) - Press Telegraph (NASDAQ:ONCE)
presstelegraph.com - July 22 at 6:31 PM
streetinsider.com logoSpark Therapeutics (ONCE), Pfizer (PFE) Receive FDA Breakthrough Therapy Designation for SPK-9001 as ... - StreetInsider.com (NASDAQ:ONCE)
www.streetinsider.com - July 22 at 6:31 PM
News IconSpark Therapeutics Incorporated (NASDAQ:ONCE) Shorted Shares Decreased By 2.76% - Consumer Eagle (NASDAQ:ONCE)
www.consumereagle.com - July 22 at 6:31 PM
News IconSpark Therapeutics, Inc. (NASDAQ:ONCE): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:ONCE)
www.engelwooddaily.com - July 22 at 6:31 PM
rttnews.com logoFDA Grants Breakthrough Therapy Designation For Spark, Pfizer's SPK-9001 (NASDAQ:ONCE)
www.rttnews.com - July 21 at 9:32 AM
thestreet.com logo13 Companies to Watch From MIT's Smart 50 List, Including 4 Buys (NASDAQ:ONCE)
www.thestreet.com - July 21 at 7:48 AM
finance.yahoo.com logoSpark Therapeutics and Pfizer Announce Receipt of FDA Breakthrough Therapy Designation for SPK-9001 for the Treatment of Hemophilia B (NASDAQ:ONCE)
finance.yahoo.com - July 21 at 7:30 AM

Social

Spark Therapeutics (NASDAQ:ONCE) Chart for Saturday, September, 24, 2016


Last Updated on 9/24/2016 by MarketBeat.com Staff